Aherium's (ASX:ADR) share price is up 50% this morning, following news its received U.S. FDA (Food and Drug Administration) clearance for Teva’s ProAir® and Albuterol Sulphate inhaler users to remotely monitor physiological parameters.
It's the fourth FDA 510(k) market clearance of the next-generation Hailie sensors and Adherium has progressed from covering 11% to 79% of the U.S. top 20 branded inhaler medications by sales volume.
The company says the clearance provides superior data and insights into patient inhaler technique and usage, giving healthcare providers immediate, real-time feedback to enhance patient care.
Adherium also offers Remote Therapeutic Monitoring to cover 91% of the U.S. top 20 branded inhalers, enabling access by healthcare providers for the CMS Remote Therapeutic Monitoring reimbursement codes published in 2022.